Literature DB >> 10175975

The Danish approach to standards for economic evaluation methodologies.

A Alban1, M Gyldmark, A V Pedersen, J Søgaard.   

Abstract

Standards for economic evaluation have now been proposed in several countries. The background for this article is a report commissioned in 1994 by the Danish health authorities (the National Board of Health and the Danish Ministry of Health) on the state of the art of economic evaluation: are the methods ready to be used for systematic decision-making in the Danish healthcare sector? The themes of this article are the attitude towards economic evaluation of medical technologies and healthcare services in Denmark, the areas for application and the desirability and feasibility of a standard set of methods for conducting economic evaluations. In addition, the current state of methodologies in economic evaluation is briefly outlined. On the background of a roundtable discussion of interested parties, the Danish health authorities have decided to introduce economic evaluation of new pharmaceutical products, on a voluntary basis for 2 to 3 years, when application has been made for public reimbursement.

Mesh:

Year:  1997        PMID: 10175975     DOI: 10.2165/00019053-199712060-00003

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  4 in total

1.  Indirect costs in economic studies: confronting the confusion.

Authors:  M A Koopmanschap; F F Rutten
Journal:  Pharmacoeconomics       Date:  1993-12       Impact factor: 4.981

Review 2.  Generic and disease-specific measures in assessing health status and quality of life.

Authors:  D L Patrick; R A Deyo
Journal:  Med Care       Date:  1989-03       Impact factor: 2.983

3.  Towards a new approach for estimating indirect costs of disease.

Authors:  M A Koopmanschap; B M van Ineveld
Journal:  Soc Sci Med       Date:  1992-05       Impact factor: 4.634

Review 4.  Why is the pharmaceutical industry investing increasing amounts in health economic evaluations?

Authors:  F Andersson
Journal:  Int J Technol Assess Health Care       Date:  1995       Impact factor: 2.188

  4 in total
  6 in total

1.  The revised Canadian Guidelines for the Economic Evaluation of Pharmaceuticals.

Authors:  J L Glennie; G W Torrance; J F Baladi; C Berka; E Hubbard; D Menon; N Otten; M Rivière
Journal:  Pharmacoeconomics       Date:  1999-05       Impact factor: 4.981

2.  Pharmacoeconomics in the new millennium. A pharmaceutical industry perspective.

Authors:  R Thwaites; R J Townsend
Journal:  Pharmacoeconomics       Date:  1998-02       Impact factor: 4.981

3.  Do economic evaluations of targeted therapy provide support for decision makers?

Authors:  Ilia L Ferrusi; Natasha B Leighl; Nathalie A Kulin; Deborah A Marshall
Journal:  J Oncol Pract       Date:  2011-05       Impact factor: 3.840

Review 4.  Do economic evaluations of targeted therapy provide support for decision makers?

Authors:  Ilia L Ferrusi; Natasha B Leighl; Nathalie A Kulin; Deborah A Marshall
Journal:  Am J Manag Care       Date:  2011-05       Impact factor: 2.229

5.  Early parenteral nutrition in critically ill patients with short-term relative contraindications to early enteral nutrition: a full economic analysis of a multicenter randomized controlled trial based on US costs.

Authors:  Gordon S Doig; Fiona Simpson
Journal:  Clinicoecon Outcomes Res       Date:  2013-07-22

6.  Early enteral nutrition in critical illness: a full economic analysis using US costs.

Authors:  Gordon S Doig; Hélène Chevrou-Séverac; Fiona Simpson
Journal:  Clinicoecon Outcomes Res       Date:  2013-08-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.